Acharya Balkrishna, Chief Executive Officer (CEO) of Patanjali, said that all procedures were followed to manufacture the medicine, Coronil, and they have not done anything wrong while obtaining the licence.
"We have followed all procedures to manufacture the medicine (Coronil). We applied for the licence based on classical evidence of the compounds used in the medicine. We worked on the compounds and put out the results of the clinical trial before people," Acharya Balkrishna said.
"We have not done anything wrong while obtaining the licence. We did not advertise the medicine (Coronil), we just tried to tell people about the effects of the medicine," he added.
ALSO READ: Coronavirus LIVE: India cases rise to 491,170; global tally past 9.7 mn
This comes after MoS for the Union Ayush Ministry Shripad Naik said that Patanjali Ayurved should not have advertised its newly-launched ayurvedic drugs for Covid-19 before getting final approvals.
"They (Patanjali Ayurved) should not have advertised it (Coronil) before getting final approvals. We have asked them to complete the requisite procedures. They have sent it to us and we will make a decision soon," Naik said.
The AYUSH Ministry had said on Tuesday that it has taken cognizance of news in the media about Ayurvedic medicines developed for the treatment of COVID-19 by Patanjali Ayurved Ltd, Haridwar and said the company has been asked to "stop advertising/publicising such claims till the issue is duly examined".
Patanjali Ayurved on Tuesday launched 'Coronil and Swasari' claiming it to be Ayurvedic cure for treating Covid-19 and said clinical trials have shown favourable results.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.